The US firm Vical has shown that innovation is still alive and kicking in the industry – Phase I data on its potential SARS vaccine has been published only 19 months after the release of the genetic sequence of the coronavirus responsible for severe acute respiratory syndrome.
The US firm Vical has shown that innovation is still alive and kicking in the industry – Phase I data on its potential SARS vaccine has been published only 19 months after the release of the genetic sequence of the coronavirus responsible for severe acute respiratory syndrome.
The results of the Phase I study of the vaccine, conducted at the US National Institutes of Health, were published...
Create an account to read this article
Already a subscriber?
The FDA go-ahead makes it the first for a BTK inhibitor in immune thrombocytopenia. Sanofi hopes it will mark the start of a number of indications for rilzabrutinib.
Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.
A China-only Phase III study for the anti-BAFF/APRIL fusion protein marks the latest positive dataset for the drug, which Vor licensed from China-based RemeGen in June.
Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.
Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.
The drugmaker announced topline results for the CDK4/6 inhibitor in early HR-positive, HER2-negative breast cancer, giving it a competitive edge over Novartis’s Kisqali.
Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.
